Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer

Immune checkpoint inhibitors (ICIs) have brought impressive clinical benefits in a variety of malignancies over the past years, which dramatically revolutionized the cancer treatment paradigm. Monotherapy or in combination with chemotherapy of ICIs targeting programmed death 1/programmed death ligan...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shumin, Zhang, Chengyan, Pang, Guanchao, Wang, Pingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596386/
https://www.ncbi.nlm.nih.gov/pubmed/33178229
http://dx.doi.org/10.3389/fimmu.2020.603157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596386/
https://www.ncbi.nlm.nih.gov/pubmed/33178229
http://dx.doi.org/10.3389/fimmu.2020.603157

Ejemplares similares